Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling

Related Experiment Video

Updated: Jun 12, 2026

Tumor Allotransplantation in Drosophila melanogaster with a Programmable Auto-Nanoliter Injector
05:06

Tumor Allotransplantation in Drosophila melanogaster with a Programmable Auto-Nanoliter Injector

Published on: February 2, 2021

Anastasia Z Kalea1, Fiona See, Evis Harja

  • 1Division of Surgical Science, Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.

Cancer Research
|June 24, 2010
PubMed

Insights

A newly discovered RAGE splice variant 1 (RAGEv1) acts as a tumor suppressor. This soluble RAGE form inhibits cancer growth, invasion, and angiogenesis by downregulating the JNK pathway, offering new therapeutic avenues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Receptor for advanced glycation end products (RAGE) and its ligands are implicated in cancer development and metastasis.
  • The precise mechanisms by which RAGE influences tumorigenesis are not fully understood.

Purpose of the Study:

  • To define the functional role of a specific RAGE splice variant, RAGE splice variant 1 (RAGEv1).
  • To investigate RAGEv1's potential as a tumor suppressor and its impact on RAGE-mediated signaling pathways.

Main Methods:

  • Analysis of RAGEv1 expression in human tumors (lung, prostate, brain) versus matched controls.
  • Overexpression of RAGEv1 in tumor cells to assess its effects on RAGE ligand-induced gene expression, tumor formation, invasion, and angiogenesis.
  • Investigation of signal transduction pathways, specifically the c-jun-NH(2)-kinase (JNK) pathway.

Main Results:

  • RAGEv1 was found to be downregulated in multiple cancer types.
  • Overexpression of RAGEv1 suppressed tumor formation, cell invasion, and angiogenesis.
  • RAGEv1 significantly inhibited RAGE ligand-stimulated gene expression and suppressed JNK pathway signaling.
  • Tumors expressing RAGEv1 showed reduced size and JNK activation compared to wild-type tumors.

Conclusions:

  • RAGEv1 functions as a novel endogenous suppressor of tumorigenesis and metastasis.
  • RAGEv1 inhibits cancer progression by modulating RAGE ligand signaling and suppressing the JNK pathway.
  • RAGEv1 represents a potential new target for cancer therapy.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...